Immunomodulation and therapeutic characterization of thymosin fraction five.
作者信息
Talmadge J E, Uithoven K A, Lenz B F, Chirigos M
出版信息
Cancer Immunol Immunother. 1984;18(3):185-94. doi: 10.1007/BF00205510.
Abstract
In this report we describe the characterization of the immunomodulatory efficiency and therapeutic properties of thymosin fraction five (F5). We consistently observed the immunostimulation of T-cell activity in assays of allogeneic mixed lymphocyte response (MLR) and the development of cytotoxic effector cells in an allogeneic mixed lymphocyte tumor response-cell-mediated cytotoxicity assay (MLTR-CMC). No induction of suppressor cell activity was observed. Thymosin F5 also acted successfully as an adjuvant when admixed with irradiated tumor cells. We were unable to demonstrate either NK cell or macrophage activation by thymosin F5. Therapeutic protocols using thymosin F5 and directed against pre-existing experimental and spontaneous metastases, had a significant immunotherapeutic potential.
摘要
相似文献
1
Immunomodulation and therapeutic characterization of thymosin fraction five.
Cancer Immunol Immunother. 1984;18(3):185-94. doi: 10.1007/BF00205510.
2
The effect of experimental conditions on the assessment of T cell immunomodulation by biological response modifiers (thymosin fraction five).
Immunopharmacology. 1984 Feb;7(1):17-26. doi: 10.1016/0162-3109(84)90004-3.
3
Thymosin: immunomodulatory and therapeutic characteristics.
Prog Clin Biol Res. 1984;161:457-65.
4
Immunoregulatory effects of fraction 5 thymus peptides. I. Thymosin alpha 1 enhances while thymosin beta 4 suppresses the human autologous and allogeneic mixed lymphocyte reaction.
Immunopharmacology. 1987 Apr;13(2):133-41. doi: 10.1016/0162-3109(87)90050-6.
5
The biological effect of three thymosin fraction 5 polypeptides in the murine mixed lymphocyte reaction.
Immunology. 1985 Apr;54(4):723-30.
6
7
Immunomodulatory and therapeutic properties of bestatin in mice.
Cancer Res. 1986 Sep;46(9):4505-10.
8
Suppressive effect of thymosin fraction 5 on proliferation of cultured human T lymphocytes.
Immunopharmacology. 1986 Dec;12(3):233-40. doi: 10.1016/0162-3109(86)90007-x.
9
High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
Anticancer Res. 1998 Sep-Oct;18(5A):3571-8.
10
Thymosin-induced differentiation of murine thymocytes in allogeneic mixed lymphocyte cultures.
Ann N Y Acad Sci. 1975 Feb 28;249:145-53. doi: 10.1111/j.1749-6632.1975.tb29064.x.
引用本文的文献
1
Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?
Vitam Horm. 2016;102:179-207. doi: 10.1016/bs.vh.2016.04.008. Epub 2016 May 27.
2
Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers.
Springer Semin Immunopathol. 1985;8(4):429-43. doi: 10.1007/BF01857395.
3
Thymosins and anti-thymosins: properties and clinical applications.
Med Oncol Tumor Pharmacother. 1986;3(3-4):211-21. doi: 10.1007/BF02934997.
4
Thymic hormones--a clinical update.
Springer Semin Immunopathol. 1986;9(1):1-18. doi: 10.1007/BF00201901.
本文引用的文献
1
ANTIGENIC PROPERTIES OF LYMPHOMAS INDUCED BY THE MOLONEY AGENT.
J Natl Cancer Inst. 1964 Mar;32:547-68.
2
A transplantable mast-cell neoplasm in the mouse.
J Natl Cancer Inst. 1957 Apr;18(4):587-601.
3
Tumor cytotoxicity of rat alveolar macrophages activated in vitro by endotoxin.
J Reticuloendothel Soc. 1980 Mar;27(3):269-79.
4
Induction of terminal deoxynucleotidyl transferase and Lyt antigens with thymosin: identification of multiple subsets of prothymocytes in mouse bone marrow and spleen.
Proc Natl Acad Sci U S A. 1981 Apr;78(4):2469-73. doi: 10.1073/pnas.78.4.2469.
5
Macrophage content of metastatic and nonmetastatic rodent neoplasms.
J Immunol. 1981 Jun;126(6):2245-8.
6
Resistance to L1210 mouse leukemia cells in moderately protein-malnourished BALB/c mice treated in vivo with thymosin fraction V.
Cancer Res. 1982 Jun;42(6):2139-45.
7
Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers.
J Biol Response Mod. 1984;3(1):88-109.
8
Enhancement of murine thymocyte cytotoxic T cell responses by thymosin.
Immunopharmacology. 1983 Jun;6(1):65-74. doi: 10.1016/0162-3109(83)90017-6.
9
Regulation of in vitro generation of cell-mediated cytotoxicity. II. Characterization of thymosin-induced suppressor T cells.
Immunopharmacology. 1980 Dec;2(4):301-12. doi: 10.1016/0162-3109(80)90014-4.
10
Regulation of in vitro generation of cell-mediated cytotoxicity. In vitro induction of suppressor T lymphocytes by thymosin.
J Reticuloendothel Soc. 1980 Aug;28(2):141-9.
Zotero 插件